scholarly journals Detection of Lung Cancer and EGFR Mutation by Electronic Nose System

2017 ◽  
Vol 12 (10) ◽  
pp. 1544-1551 ◽  
Author(s):  
Dekel Shlomi ◽  
Manal Abud ◽  
Ori Liran ◽  
Jair Bar ◽  
Naomi Gai-Mor ◽  
...  
Author(s):  
Ping Wang ◽  
Fan Gao ◽  
Xusheng Zhang ◽  
Min Wang

In this chapter, the authors introduce three typical applications of electronic nose, including the diagnosis of lung cancer and gastrointestinal diseases and food freshness detection. Firstly, an electronic nose system intended for lung cancer screening employs semiconductor and electrochemical sensors to compose an array in a chamber to conduct breath analysis with pre-concentration and multiple desorption procedures. Secondly, a design of virtual electronic nose was presented to detect the concentration of hydrogen, methane, and carbon dioxide in breath for the diagnosis of small intestinal bacterial overgrowth. Finally, combined with the metal oxide semiconductor sensors and electrochemical sensors array, the small size electronic nose system is to identify the freshness and classify different kinds of food stored in the refrigerator.


2021 ◽  
Vol 131 ◽  
pp. 104294
Author(s):  
Ke Chen ◽  
Lei Liu ◽  
Bo Nie ◽  
Binchun Lu ◽  
Lidan Fu ◽  
...  

2017 ◽  
Vol 12 (1) ◽  
pp. S342 ◽  
Author(s):  
Dekel Shlomi ◽  
Manal Abud-Hawa ◽  
Ori Liran ◽  
Jair Bar ◽  
Naomi Gai Mor ◽  
...  

2021 ◽  
Vol 13 ◽  
pp. 175883592098764
Author(s):  
Ryota Shibaki ◽  
Hiroaki Akamatsu ◽  
Terufumi Kato ◽  
Kazumi Nishino ◽  
Morihito Okada ◽  
...  

Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is a standard treatment in EGFR-mutated advanced non-small-cell lung cancer (NSCLC); however, previous data have suggested that EGFR-TKI has limited potential as adjuvant therapy. On the contrary, based on subset analysis with the immune checkpoint inhibitor (ICI) plus platinum-doublet chemotherapy in advanced NSCLC with EGFR mutation, we hypothesized that this combination was worth testing as adjuvant therapy in patients with EGFR-mutated NSCLC. Methods: Herein, we introduce our phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected NSCLC with EGFR mutation. Accrued patients will be pathological stage II–IIIA with completely resected NSCLC and whose tumors have EGFR mutation. Treatment comprises four cycles of cisplatin plus vinorelbine combined with atezolizumab followed by maintenance with atezolizumab. The primary endpoint is the disease-free survival (DFS) rate at 2 years. Secondary endpoints are DFS, overall survival, and safety. In total, 18 patients will be enrolled in this study. Discussion: Ongoing phase III trials of adjuvant ICI allow the inclusion of patients with EGFR mutation, but our current trial will provide the earliest clinical data on the efficacy of platinum-doublet chemotherapy with atezolizumab.


Sign in / Sign up

Export Citation Format

Share Document